More Options Available With a Quadripolar LV Lead pRovidE In-clinic Solutions to CRT Challenges (MORE-CRT)

This study is currently recruiting participants.
Verified August 2012 by St. Jude Medical
Sponsor:
Information provided by (Responsible Party):
St. Jude Medical
ClinicalTrials.gov Identifier:
NCT01510652
First received: November 30, 2011
Last updated: August 20, 2012
Last verified: August 2012
  Purpose

This investigation is designed with the hypothesis that using a quadripolar left ventricular lead results in less interventions when dealing with high pacing thresholds and Phrenic Nerve Stimulation (PNS), both at implant and during follow-up, compared to standard bipolar left ventricular leads.


Condition Intervention
Postoperative Cardiac Complication
Heart Failure,
Left Ventricular Cardiac Dysfunction
Inappropriate Phrenic Nerve Stimulation
Perioperative/Postoperative Complications
Procedure: Standard Left Ventricular (LV) lead
Device: Quartet Left Ventricular (LV) lead

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: More Options Available With a Quadripolar Left Ventricular (LV) Lead pRovidE In-clinic Solutions to Cardiac Resynchronization Therapy (CRT) Challenges

Resource links provided by NLM:


Further study details as provided by St. Jude Medical:

Primary Outcome Measures:
  • Lead performance [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    measures the intra-procedural and post-procedural performance of St. Jude Medical Left Ventricular (SJM LV) quadripolar Quartet lead compared to any other standard bipolar Left Ventricular (LV) lead


Secondary Outcome Measures:
  • Percentage of Cardiac Resynchronization Therapy responders [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Percentage of Cardiac Resynchronization Therapy (CRT) responders measured by a decrease of at least 10% of Left Ventricle End-Systolic Volume (LVESV)

  • Implant duration [ Time Frame: Until completion of implantation procedure ] [ Designated as safety issue: No ]
    The total implant procedure duration time will be compared between the control and the treatment group.


Estimated Enrollment: 1062
Study Start Date: November 2011
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Study Group
Patients in the Study group will be implanted with St. Jude Medical (SJM) quadripolar Left Ventricular (LV) lead Quartet
Device: Quartet Left Ventricular (LV) lead
Implantation of quadripolar Left ventricular (LV) lead Quartet
Active Comparator: Control Group
Patients in the Control Group will be implanted with a standard (regulatory approved and commercially available) bipolar left ventricular lead from other companies (non St. Jude Medical leads)
Procedure: Standard Left Ventricular (LV) lead
Implantation of standard Left Ventricular (LV) lead

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients are indicated for Cardiac Resynchronization Therapy with Defibrillation backup device (CRT-D) implantation, as per current international certified guidelines
  • Patients age is 18 years or greater
  • Patients must indicate their understanding of the study and willingness to participate by signing the appropriate informed consent form
  • Patients must be willing and able to comply with all study requirements

Exclusion Criteria:

  • Patients with a life expectancy <12 months.
  • Patients who are or may potentially be pregnant.
  • Patient has suffered any of the following in the 4 weeks prior to enrolment:

    • Myocardial Infarction (MI)
    • Coronary Artery Bypass Graft (CABG)
    • Unstable Angina Pectoris
  • Patient has primary valvular disease which has not been corrected
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01510652

Contacts
Contact: Giuseppe Boriani, Prof. giuseppe.boriani@unibo.it

Locations
Belgium
Hopital La Citadelle Not yet recruiting
Liège, Belgium
Contact: Jean Borland, Dr.            
Principal Investigator: Jean Borland, Dr.            
Germany
Klinikum Ludenscheid Recruiting
Ludenscheid, Germany
Contact: Bernd Lemke, Prof.            
Principal Investigator: Bernd Lemke, Prof.            
Ireland
Beaumont Hospital Not yet recruiting
Dublin, Ireland
Contact: Ricky Sheahan, Dr.            
Principal Investigator: Ricky Sheahan, Dr.            
Italy
Policlinico S. Orsola & Malpighi Not yet recruiting
Bologna, Italy
Contact: Giuseppe Boriani, Prof.     +390516363598     giuseppe.boriani@unibo.it    
Principal Investigator: Giuseppe Boriani, Prof.            
Ospedale SS. Annunziata Not yet recruiting
Taranto, Italy
Contact: Vitantonio Russo, Prof.            
Principal Investigator: Vitantonio Russo, Prof.            
Netherlands
MC Haaglanden Recruiting
Den Haag, Netherlands
Contact: Alexander Wardeh, Dr.         a.wardeh@mchaaglanden.nl    
Principal Investigator: Alexander Wardeh, Dr.            
Sponsors and Collaborators
St. Jude Medical
Investigators
Principal Investigator: Giuseppe Boriani, Pro. Policlinico Universitario S. Orsola e Malpighi, Bologna, Italy
  More Information

No publications provided

Responsible Party: St. Jude Medical
ClinicalTrials.gov Identifier: NCT01510652     History of Changes
Other Study ID Numbers: CR-11-006-HF-ID
Study First Received: November 30, 2011
Last Updated: August 20, 2012
Health Authority: Belgium: Ethics Committee
Germany: Ethics Commission
Italy: Ethics Committee
Netherlands: Independent Ethics Committee

Keywords provided by St. Jude Medical:
Cardiac Resynchronization therapy,
Heart Failure,
Left Ventricular Lead,
Quadripolar Left ventricular Lead,
Phrenic Nerve Stimulation,
Intra and post operative related complications

Additional relevant MeSH terms:
Heart Failure
Postoperative Complications
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on June 18, 2013